Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/134797COMPARTIR / EXPORTAR:
 SHARE
 CORE
BASE
|
|
| Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
| Título: | Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma |
Autor: | Dimopoulos, Meletios A.; Palumbo, Antonio; Moreau, Philippe; Delforge, Michel; Cavo, Michele; Ludwig, Heinz; Mateos, Maria Victoria; San Miguel, Jesús F. CSIC ORCID | Fecha de publicación: | 2014 | Editor: | Nature Publishing Group | Citación: | Leukemia 28(8): 1573-1585 (2014) | Resumen: | In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, whereas dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who develop neutropenia, thrombocytopaenia and other grade 3-4 adverse events during pomalidomide therapy. Guidance on the prevention and management of infections and venous thromboembolism is provided, based on the available clinical evidence and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age, renal impairment or unfavourable cytogenetic features, is also discussed. | Descripción: | This work is licensed under a Creative Commons Attribution 3.0 Unported License.-- et al. | Versión del editor: | http://dx.doi.org/10.1038/leu.2014.60 | URI: | http://hdl.handle.net/10261/134797 | DOI: | 10.1038/leu.2014.60 | Identificadores: | doi: 10.1038/leu.2014.60 e-issn: 1476-5551 issn: 0887-6924 |
| Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
| Fichero | Descripción | Tamaño | Formato | |
|---|---|---|---|---|
| refractorymultiplemyeloma.pdf | 690,65 kB | Adobe PDF |  Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
37
checked on 14-abr-2024
SCOPUSTM
Citations
99
checked on 13-abr-2024
WEB OF SCIENCETM
Citations
81
checked on 23-feb-2024
Page view(s)
350
checked on 19-abr-2024
Download(s)
278
checked on 19-abr-2024
